A 28-year-old woman, 15 weeks pregnant, consulted for cervical ache and left laterocervical mass. Imaging scans revealed a large mediastinal mass that had spread to supraclavicular and left axillar spaces, including cervicobrachial plexus. Pathological anatomy confirmed an unclassifiable lymphoma, with intermediate features between diffuse large B-cell lymphoma and classical Hodgkin's lymphoma. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) therapy was started with partial response. But due to disease progression, an elective caesarean section was performed (30th week of pregnancy) to begin a chemotherapy regime incompatible with pregnancy. Despite acute complications related to prematurity, the newborn could be discharged from hospital at 45 days of life. The patient did not respond to the second treatment line and she is currently undergoing a third chemotherapy regime. Given the unusual occurrence of lymphoma during pregnancy, multidisciplinary teamwork between haematologists, neonatologists and obstetricians is essential to achieve the best maternal-fetal outcome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919555 | PMC |
| http://dx.doi.org/10.1136/bcr-2020-239462 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study.
Hematol Oncol
January 2025
Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Polatuzumab vedotin plus R-CHP (Pola-R-CHP) is approved as a new standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) based on the POLARIX trial. However, real-world data on its efficacy and safety in unselected patients is lacking. We conducted a retrospective cohort study to evaluate Pola-R-CHP versus R-CHOP outcomes in routine clinical practice in China.
View Article and Find Full Text PDFNon-Hodgkin's primary lymphoma involving the genitourinary tract: histopathological experience from two tertiary hospitals, Western region, Saudi Arabia.
Am J Clin Exp Urol
October 2024
Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center Jeddah, Saudi Arabia.
Article Synopsis
- The study focuses on primary lymphoid neoplasms in the urinary tract and male genital organs, which are rare and make up less than 5% of extranodal lymphomas.
- Researchers analyzed cases diagnosed from 2005 to 2020, examining pathology slides from 11 patients, predominantly middle-aged, finding a female predominance in urinary bladder and ureter lymphomas.
- The findings confirm that diffuse large B-cell lymphoma (DLBCL) is the most common subtype, but emphasize the importance of thorough classification and diagnosis using techniques like immunohistochemistry to accurately identify various lymphoma types.
Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.
Int J Mol Sci
October 2024
Department of Physical Chemistry, Vinca Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovica Alasa 12-14, 11000 Belgrade, Serbia.
Diffuse large B-cell lymphoma (DLBCL) is a malignancy of immense biological and clinical heterogeneity. Based on the transcriptomic or genomic approach, several different classification schemes have evolved over the years to subdivide DLBCL into clinically (prognostically) relevant subsets, but each leaves unclassified samples. Herein, we outline the DLBCL tumor biology behind the actual and potential drug targets and address the challenges and drawbacks coupled with their (potential) use.
View Article and Find Full Text PDFRefining Diagnostic Subtypes of Peripheral T-Cell Lymphoma Using a Multiparameter Approach.
Mod Pathol
November 2024
Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, Nebraska. Electronic address:
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of neoplasms, with many cases remaining unclassifiable and categorized as PTCL-not otherwise specified (PTCL-NOS). Gene expression profiling (GEP) has delineated 2 prognostic subtypes within PTCL-NOS, PTCL-TBX21 and PTCL-GATA3, characterized by distinctive transcriptomes and a different prognosis. To further evaluate the pathologic features of these subgroups, 101 PTCL cases that did not meet specific criteria for well-defined T-cell lymphoma entities underwent detailed pathologic, immunophenotypic (including T follicular helper [T] biomarkers), and GEP analyses, separating them into PTCL-NOS (n = 63) and PTCL-TFH (also known as nodal PTCL-TFH, NOS, and TFH lymphoma, NOS) (n = 38).
View Article and Find Full Text PDFNovel diagnostic method for B cell vitreoretinal lymphoma by identification of regulatory T cells and PD-1 cytotoxic T lymphocytes in the vitreous via flow cytometry.
Br J Ophthalmol
October 2024
Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Aims: To investigate the significance of regulatory T cells (Tregs) and programmed cell death 1 (PD-1) cytotoxic T lymphocytes (CTLs) in the vitreous of patients with vitreoretinal lymphoma (VRL) and uveitis.
Methods: This study involved 51 patients with VRL and uveitis, 15 males and 36 females (mean age: 72 years, range: 51-86 years), who underwent vitrectomy at the Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan, from December 2019 to February 2024. All patients underwent lymphocyte surface antigen analysis via flow cytometry, and the proportion of Tregs in CD4 T lymphocytes and PD-1 CTLs in CD8 T lymphocytes was measured.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!